Skip to content
Review Open access

Context-dependent cGAS-STING signaling in solid tumors: biological determinants, clinical implications, and biomarker-guided therapeutic strategies

Oct 2026 · Frontiers in Immunology · Vol 17 · 0 citations · 39 references
Medicine

TL;DR

Prospective, compartment-resolved biomarker studies are needed to match agonists, delivery systems, combination regimens, or inhibitory approaches to the appropriate tumor state, and STING inhibition in chromosomal-instability-high tumors remains a promising preclinical hypothesis, not an established treatment.

Abstract

Stimulator of interferon genes (STING) agonists are intended to convert cytosolic DNA sensing into productive antitumor immunity, yet their biological effects vary substantially among tumors. Outcomes depend on the cellular compartment engaged, the amplitude and duration of signaling, tumor genotype, the immune architecture of the tumor microenvironment, and drug distribution. A critical distinction must therefore be made between chronic endogenous, tumor-cell-intrinsic cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) signaling, as may occur in chromosomally unstable tumors, and controlled pharmacological STING agonism. The former can sustain maladaptive inflammatory programs in selected experimental settings, whereas the latter can be delivered transiently and may preferentially activate dendritic cells and other host immune compartments. This narrative review examines canonical STING-TBK1-IRF3/type I interferon signaling and alternative chronic outputs; relates these mechanisms to chromosomal instability, mismatch-repair status, immune surveillance, and immune checkpoint blockade; and evaluates early clinical experience with intratumoral STING agonists. Available trials demonstrate target engagement and generally manageable toxicity, but efficacy has been limited or heterogeneous. Mismatch-repair status, tumor mutational burden, chromosomal instability, baseline interferon activity, STING pathway competence, immune-cell topology, and delivery feasibility should therefore be considered components of a candidate composite biomarker strategy rather than validated predictors. By contrast, STING inhibition in chromosomal-instability-high tumors remains a promising preclinical hypothesis, not an established treatment. Prospective, compartment-resolved biomarker studies are needed to match agonists, delivery systems, combination regimens, or inhibitory approaches to the appropriate tumor state.

Read PDF

Similar papers

Review Open access Sep 2026

Context-dependent roles of cGAS-STING signaling in glioblastoma: Therapeutic resistance, drug delivery, and heterogeneity-informed translation.

A heterogeneity-informed framework for patient stratification and precision immunotherapy development in GBM is proposed, and major translational challenges are highlighted, including blood-brain barrier penetration, cell-type-specific pathway activation, treatment-induced pathway remodeling, and biomarker selection.

Yu-Zhu Long, Tong-Cui Jiang, Yu Long et al. · 0 citations
Review Open access Sep 2026

STING-mediated tumor microenvironment remodeling: turning adaptive resistance into therapeutic vulnerability

It is proposed that rational combinations of STING agonists with Fc-engineered PD-L1/PD-L2-targeting antibodies, guided by dynamic and spatial biomarkers, could overcome resistance to conventional immune checkpoint blockade in tumors with minimal T-cell infiltration but targetable tumor vasculature.

Akash R. Boda, E. Bolli, A. Salameh et al. · 0 citations
Review Open access Oct 2026

Context-dependent cGAS–STING signaling in inflammatory bowel disease: cell specificity, lesion state, and therapeutic windows

Whether cyclic GMP–AMP synthase (cGAS)–stimulator of interferon genes (STING) signaling should be inhibited in inflammatory bowel disease (IBD) cannot be answered from pathway abundance alone. Canonical ER–Golgi–TBK1–IRF3/NF-κB signaling can amplify intestinal inflammation, whereas nuclear STING–AHR signaling, T-cell-i...

Hui-Xi Bian, Wen-Jing Jin, Yu-Hong Chen et al. · 0 citations
Review Open access Oct 2026

The cGAS-STING pathway in ovarian cancer: from genomic instability to immunotherapeutic vulnerability

Ovarian cancer remains the most lethal gynecologic malignancy, a status largely attributable to late-stage diagnosis and inevitable chemoresistance. The cGAS-STING pathway, a cornerstone of innate immune surveillance, has emerged as a critical nexus linking genomic instability to antitumor immunity—a connection of part...

Hui-Hui Chen, Feng-Xian Ni, Dong-Hui Huang et al. · 0 citations
Review Sep 2026

The cGAS-STING signaling in hepatocellular carcinoma: A spatiotemporally gated immune switch linking pro-tumorigenic immune evasion and anti-tumor therapeutic response.

Hepatocellular carcinoma (HCC) arises from chronic inflammation and immune tolerance, posing substantial challenges for immunotherapy. The cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) signaling is a central immunological hub linking innate immune sensing to adaptive immune responses in tumors. In...

Yuan Chen, Yu-Hong An, Chao-Qun Wang et al. · 0 citations
Review Sep 2026

The cGAS-STING pathway: mechanistic basis, dual biological functions and translational therapeutic advances

This review systematically investigates the distinct functional states and biological behaviors of the cGAS-STING pathway under a variety of disease conditions to provide comprehensive theoretical references and research directions for follow-up basic mechanistic studies and clinical transformation of cGAS-STING target...

Minjue Shan, Yan Liao, Zi-You Lin et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.